Saturday, August 29, 2015

J&J's Janssen unit gets federal subpoena over opioid painkiller Nucynta

Johnson & Johnson said in an SEC filing that federal investigators in Atlanta are examining the company's sales tactics, including payments to health-care providers, for its opioid painkillers, Nucynta.

J&J's Janssen unit gets federal subpoena over opioid painkiller Nucynta

0 comments

Johnson & Johnson said in a filing with the Securities and Exchange Commission that federal investigators in Atlanta are examining the company's sales tactics, including payments to health-care providers, for its opioid painkillers, Nucynta IR and Nucynta ER.

J&J filed its second quarter financial report (10-Q, here) on Friday. The item on the subpoena is on page 34. J&J's Janssen Pharmaceuticals makes Nucynta and got the subpoena from the Atlanta regional Office of the Department of Health and Human Services, Office of Inspector General.

The OIG is "seeking production of documents and information regarding: (1) the sales, marketing and promotional practices, including the remuneration of healthcare providers, related to Nucynta IR and Nucynta ER; and (2) any studies, reports and/or complaints regarding the safety and/or actual or potential side effects of Nucynta IR and Nucynta ER."

J&J said it is responding to the subpoena.

Opioid painkillers can be highly addictive. Accidental overdose deaths have passed those caused by illegal street drugs cocaine and heroin.

Federal agencies, including several branches of the Justice Department, have focused on trying to stop so-called pill mills. These are often store front operations, which proliferated in Florida. When authorities came down on such operations in Florida, the pill-mill crowd moved north to Georgia.

 

 

0 comments
We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy:

Philly.com comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by Philly.com staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
 
comments powered by Disqus
About this blog
David Sell blogs about the region's pharmaceutical industry. Follow him on Facebook.

Portions of this blog may also be found in the Inquirer's Sunday Health Section.

Reach David at dsell@phillynews.com or 215-854-4506.

David Sell
Also on Philly.com:
letter icon Newsletter